Neogen Chemicals Q1FY26 – 99 P/E, ₹348 Cr Fire, and Lithium Dreams That Burn Hotter Than Their Plants
1. At a Glance
Neogen Chemicals Ltd (CMP ₹1,519, Market Cap ₹4,008 Cr) is that peculiar cocktail of “high-tech lithium narrative” and “old-school bromine aunties’ chemical shop” rolled into one. In the last 3 months, the stock gave investors a -8.3% reality check, while 1-year return is -29.7% (yes, your SIP is now an RIP). Trading at a nosebleed P/E of 99.1, a P/B of 5.08, and a ROE of 5.59%, this smallcap is asking for respect while leaking profits like a bucket with holes. Q1FY26 saw revenue of ₹187 Cr (+4% QoQ), PAT of ₹10.3 Cr (-11% QoQ) — and oh, a ₹348 Cr fire accident at Dahej, offset by ₹80 Cr insurance. Basically, Neogen is selling the EV future dream, but for now, shareholders are holding a jhola of volatility.
2. Introduction
Imagine a company that manufactures “lithium electrolytes” — the fairy dust of electric vehicles — but also still relies on bromine like your dad’s lab experiment. That’s Neogen. Born in 1991, back when India’s liberalization was opening the floodgates, Neogen has evolved from 20 products in 2001 to 246 products in FY25.
But here’s the catch: the growth story is less like Reliance Jio (explosive) and more like Doordarshan serials (slow, steady, slightly boring, interrupted by random fires). Investors bought in thinking they’re funding India’s Tesla battery dream, but the financials scream “chemicals with extra stress.”
The stock trades at valuations higher than Gujarat Fluorochemicals or even Pidilite — companies that actually mint consistent cash. Neogen, meanwhile, is juggling capex worth ₹1,500 Cr, a subsidiary for lithium electrolytes, and a JV with Morita Japan — while current utilization levels at plants are as low as 20% (Vadodara). Talk about aspirational capacity building.
So what is Neogen? A chemical innovator? A lithium story stock? Or just another smallcap promising the moon and delivering periodic insurance claims? Let’s investigate.
3. Business Model – WTF Do They Even Do?
Think of Neogen as a chemical general store with a premium “EV future” marketing campaign. They operate in two segments:
Organic Chemicals (84% of revenue) – bromine compounds and intermediates for pharma, agro, and fragrances. This is their bread and butter — or rather, bromine and butter.
Inorganic Chemicals (16% of revenue) – lithium-based salts and specialty inorganics, pitched as the EV battery enabler.
Applications? Everywhere: medicines (pharma), crop protection (agro), masala chai fragrances (okay, flavours & fragrances), semiconductors, batteries, and construction chemicals. Their clientele includes Aurobindo, Divis, Sun Pharma, Piramal, Voltas, Kirloskar — basically anyone with a lab coat and a cheque book.
But here’s the kicker: Neogen is still the largest importer of lithium carbonate & hydroxide for 30 years. Translation: India’s lithium dream still depends on imports; Neogen’s edge is relationships, not mines.
And yet, they have positioned themselves as the “only company outside China” making organolithium (after acquiring BuLi Chem). Cute. But with 99 P/E, the market clearly believes they’re one lithium-ion away from becoming the Ambani of electrolytes.
Question to you: would you trust a company to build EV battery electrolytes when their existing plant utilization ranges between 20–50%?
4. Financials Overview
Source table
Metric
Latest Qtr (Q1FY26)
YoY Qtr (Q1FY25)
Prev Qtr (Q4FY25)
YoY %
QoQ %
Revenue
₹187 Cr
₹180 Cr
₹203 Cr
+3.9%
-7.9%
EBITDA
₹32 Cr
₹31 Cr
₹36 Cr
+3.2%
-11.1%
PAT
₹10.3 Cr
₹11 Cr
₹11.6 Cr
-6.4%
-11.2%
EPS (₹)
3.9
4.35
3.79
-10.3%
+2.9%
Annualised EPS: ~₹15.6 → P/E ≈ 97x. “P/E not meaningful” would have been more honest.
Commentary: They grew revenue, but profits took a beating thanks to fire losses and insurance accounting. With margins flat at ~17%, this is less of a Ferrari and more of
